Lifecore Biomedical, Inc. is a company specializing in the development and manufacturing of advanced biomaterials and medical devices
They focus on products that improve patient outcomes, particularly in the fields of orthopedic, ophthalmic, and surgical applications. Lifecore's expertise lies in the production of hyaluronic acid and its derivatives, which are used in a variety of therapeutic and aesthetic treatments. The company collaborates with healthcare professionals and organizations to innovate and enhance the effectiveness of their biomedical solutions, contributing to advancements in medical technology and patient care.
Company Seeking to Remove Convertible Preferred Stock Exchange Cap to Permit Potential Conversion of Series A Preferred Stock as Contemplated by the Series A Preferred Stock Terms
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQLFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California.
Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company’s Balance Sheet and Overall Financial Position
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQLFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it hosted a virtual investor day prior to market open during which Lifecore’s senior management team discussed the company’s business and strategy for growth in the future, among other topics. A replay of the event is available via webcast and can be accessed by visiting the Events & Presentations section of Lifecore’s investor web page at: https://ir.lifecore.com/events-presentations.
CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQLFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs, the company’s president and chief executive officer, will be a featured speaker in a fireside chat at the upcoming Stephens Annual Investment Conference. The conference is being held November 19-21, 2024, in Nashville, Tennessee.
CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQLFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will take place from 8:00 – 9:30 a.m. Eastern Time and be available via webcast. During the event, members of Lifecore’s senior management team will discuss the company’s business and strategy for growth in the future, among other topics.
CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQLFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the first quarter of fiscal year 2025 on Friday, October 4, 2024, prior to market open and will host a webcast at 8:30 a.m. Eastern Time. Members of Lifecore’s senior management team will discuss financial results for the first quarter and review recent corporate developments.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. (“Lifecore” or “the Company”) (NASDAQLFCR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQLFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options
